Boehringer advances oral therapy for geographic atrophy

Boehringer advances oral therapy for geographic atrophy

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss

Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.